Unknown

Dataset Information

0

Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study.


ABSTRACT: Juvenile idiopathic arthritis (JIA) is an umbrella term for seven distinct chronic immune-mediated diseases. Disease-modifying anti-rheumatic drugs (DMARD) are used to treat the underlying joint inflammation as well as extra-articular manifestations. Immunosuppression is a considerable side effect of the drugs. The main goal of this study was to investigate the effect of different JIA therapies on leukocyte subpopulations, which play a role in immune-defense. Three study groups were established. The first group consisted of JIA patients treated with methotrexate solely, the second one received a combination of methotrexate (MTX) and adalimumab (ADA). The control group was made up of the patients' healthy siblings. A total of 63 children were recruited. Fourty-one children with JIA and 22 healthy controls were included in the study. The absolute number of CD3+ T-cells was significantly elevated in patients treated with biological therapy compared to healthy controls (p2 = 0.017). In contrast, the number of CD56+ natural killer cells was significantly lower in children receiving biological therapy in comparison with healthy donors (p2 = 0.039). A significant alteration was also demonstrated between patients treated with MTX and MTX/ADA group concerning CD 19+ B-cells (p3 = 0.042). This is the first study that demonstrates significant alterations in the number of B-cells and T-cells with a relative decrease of NK-cell ratios in JIA patients receiving different DMARD therapy. Clinical Trial Registration: NCT03833271. 21.01.2019.

SUBMITTER: Nagy A 

PROVIDER: S-EPMC7758242 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study.

Nagy Arnold A   Mosdosi Bernadett B   Simon Diana D   Dergez Timea T   Berki Timea T  

Frontiers in pediatrics 20201210


Juvenile idiopathic arthritis (JIA) is an umbrella term for seven distinct chronic immune-mediated diseases. Disease-modifying anti-rheumatic drugs (DMARD) are used to treat the underlying joint inflammation as well as extra-articular manifestations. Immunosuppression is a considerable side effect of the drugs. The main goal of this study was to investigate the effect of different JIA therapies on leukocyte subpopulations, which play a role in immune-defense. Three study groups were established.  ...[more]

Similar Datasets

| S-EPMC7425194 | biostudies-literature
2009-04-13 | GSE15645 | GEO
| S-EPMC4216020 | biostudies-other
2009-04-13 | E-GEOD-15645 | biostudies-arrayexpress
| S-EPMC4521899 | biostudies-other
| S-EPMC4161937 | biostudies-literature
| S-EPMC7589221 | biostudies-literature
2015-04-07 | GSE67596 | GEO
| S-EPMC3063001 | biostudies-literature
| S-EPMC4369651 | biostudies-literature